

Figure no.	Title	Page no.
Chapter 2		
2.1	Distribution of primary brain and other CNS tumors by behavior and histology	15
2.2	WHO Tumor Grading System Based on Histology and Proliferation Potential	16
2.3	Different types of primary brain tumors	16
2.4	Treatment approaches of Brain tumor- (A) Surgery, (B) Radiation and (C) Chemotherapy	17
2.5	Blood brain barrier	18
2.6	Different transport mechanisms involve in passage of drugs across BBB	19
2.7	Efflux transporters expressed on BBB	20
2.8	Albumin based nanocarriers	24
2.9	(A) Activation of TMZ in active metabolite methyl diazonium cation (MC) and (B) mechanism of DNA alkylation	54
2.10	Mechanism of action of LND	62
Chapter 3		
3.1	Calibration plot of TMZ in DD water	82
3.2	Calibration plot of TMZ in acetate buffer pH 5.5	83
3.3	Calibration curve of TMZ in plasma by SALLE-HPLC	85
3.4	Calibration curve of TMZ in plasma by HPLC method II	86
3.5	Calibration curve of TMZ in brain homogenate HPLC method II	87
3.6	Calibration curve of LND in methanol: water (50:50)	88
3.7	Scheme for the reaction pathway between LND and FLC	89
3.8	Calibration curve of LND in PBS pH 7.4 by Spectrofluorophotometer	90
3.9	Calibration curve of LND in phosphate buffer pH 5.5 by Spectrofluorophotometer	91
3.10	Calibration curve of HA by CTAB turbidimetric method	93
3.11	Calibration curve of CS by CTAB turbidimetric method	94
3.12	Calibration curve of Lf using Bradford protein assay	95

List of figures

3.13	Calibration curve of BSA using Bradford protein assay	97
Chapter 4		
4.1	FTIR spectrum of TMZ	102
4.2	FTIR spectrum of LND	103
4.3	DSC thermogram of TMZ	104
4.4	DSC thermogram of LND	104
4.5	pXRD diffractogram of TMZ	105
4.6	pXRD diffractogram of LND	105
4.7	TMZ-excipients compatibility study by FTIR where (A) Spectrum of BSA, (B) Spectrum of TMZ, (C) Spectrum of Physical mixture of BSA-TMZ, (D) Spectrum of CS and (E) Spectrum of HA	106
4.8	LND-excipients compatibility study by FTIR where (A) Spectrum of LND, (B) Spectrum of BSA, (C) Spectrum of Lf and (D) Spectrum of Physical mixture of BSA-LND -Lf	107
4.9	Stability of TMZ in different solvents where (A) Spectrum in methanol, (B) Spectrum in ethanol, (C) Spectrum in IPA and (D) Spectrum in water	108
4.10	Stability of TMZ in different stabilizers where (A) Spectrum in citrophosphate buffer pH 6.5, (B) Spectrum in tartaric acid, (C) Spectrum in sodium acetate and (D) Spectrum in sodium meta bisulphite	109
Chapter 5		
5.1	Optimization of BSA concentration	118
5.2	Optimization of solvent and pH of aqueous phase	120
5.3	Optimization of aqueous: organic phase ratio	121
5.4	Selection of organic solvent as desolvating agent	122
5.5	Optimization of Gluteraldehyde amount	124
5.6	Optimization of rate of addition of organic phase	125
5.7	Optimization of polymer: drug ratio	126
5.8	Half normal plot obtained for Particle size (A), PDI (B), Zeta potential (C) and % entrapment efficiency (D) of TNPs	129
5.9	Statistical analysis for particle size (A), PDI (B), zeta potential (C) and %	131

	entrapment efficiency (D) of TNPs	
5.10	Parameter estimates for particle size (A), PDI (B), zeta potential (C) and % entrapment efficiency (D) of TNPs	132
5.11	Contour plots showing (A) effect of organic phase volume and polymer : drug ratio on particle size; (B) effect of GA and polymer : drug ratio on particle size; (C) effect of GA and organic phase volume on particle size of TNPs	133
5.12	Contour plots showing (A) effect of organic phase volume and polymer : drug ratio on % entrapment efficiency; (B) effect of GA and polymer : drug ratio on % entrapment efficiency; (C) effect of GA and organic phase volume on % entrapment efficiency of TNPs	134
5.13	Desirability plot obtained of TNPs	136
5.14	Visual representation summarizing the effect of various independent variables on particle size (A), PDI (B), zeta potential (C) and % entrapment efficiency (D) of TNPs	138
5.15	Particle size and PDI of optimized TNPs	139
5.16	Zeta potential of optimized TNPs	139
5.17	DSC thermograms of (A) BSA, (B) TMZ, (C) PNPs and (D) TNPs	140
5.18	FTIR spectrum of BSA, TMZ, PNPs and TNPs	141
5.19	XRD diffractograms of (A) BSA, (B) TMZ, (C) PNPs and (D) TNPs	142
5.20	<i>In vitro</i> drug release study of TMZ and TNPs in sodium acetate buffer pH 5.5	143
Chapter 6		
6.1	Schematic representation of preparation of HA-TNPs	153
6.2	Optimization of HA-TNPs: (A) effect of molecular weight of HA on conjugation, (B) effect of HA : NPs ratio on conjugation and (C) effect of stirring time on conjugation. Data is represented as mean \pm SD (n = 3).	156
6.3	Schematic representation of fabrication of CS-TNPs	157
6.4	Optimization of CS-TNPs: (A) effect of CS: NPs ratio on conjugation and (B) effect of stirring time on conjugation. Data is represented as mean \pm SD (n = 3)	159
6.5	Particle size and PDI of HA-TNPs	160

6.6	Particle size and PDI of CS-TNPs	161
6.7	Zeta potential of HA-TNPs	162
6.8	Zeta potential of CS-TNPs	162
6.9	DSC thermograms of (A) BSA, (B) TMZ, (C) PNPs, (D) TNPs, (E) HA-PNPs, (F) HA-TNPs, (G) CS-PNPs and (H) CS-TNPs	164
6.10	FTIR spectrums of (A) BSA, (B) TMZ, (C) PNPs, (D) TNPs, (E) HA, (F) HA-TNPs, (G) CS and (H) CS-TNPs	166
6.11	XRD diffractograms of (A) BSA, (B) TMZ, (C) PNPs, (D) TNPs, (E) HA-PNPs (F) HA-TNPs, (G) CS-PNPs and (H) CS-TNPs	168
6.12	TEM image of (A) TNPs, (B) HA-TNPs and (C) CS-TNPs	169
6.13	<i>In vitro</i> drug release study of TMZ, TNPs, HA-TNPs and CS-TNPs in sodium acetate buffer pH 5.5	171
Chapter 7		
7.1	<i>In vitro</i> BBB passage studies for pure TMZ, TNPs and HA-TNPs after 2h, 24h and 48h	184
7.2	<i>In vitro</i> BBB passage studies for pure TMZ, TNPs and CS-TNPs after 2h, 24h and 48h. Data is represented as mean \pm SD (n = 3)	184
7.3	<i>In vitro</i> cell viability study in U-87MG cells after 24h and 72 h (A) Comparison of TMZ and TNPs, (B) Comparison of TMZ, TNPs and HA-TNPs and (C) Comparison of TMZ, TNPs and CS-TNPs. Data is represented as mean \pm SD (n = 3)	185
7.4	Cell cycle analysis of Control, Pure TMZ, TNPs and HA-TNPs on U-87 MG cells (A) flow cytometry analysis using propidium iodide staining for cell cycle analysis. (B) Percentage cell distribution at different phases of cell cycle for control cells, Pure TMZ, TNPs and HA-TNPs. Data is represented as mean \pm SD (n = 3)	187
7.5	Cell cycle analysis of Control, Pure TMZ, TNPs and CS-TNPs on U-87 MG cells (A) flow cytometry analysis using propidium iodide staining for cell cycle analysis. (B) Percentage cell distribution at different phases of cell cycle. Data is represented as mean \pm SD (n = 3)	188

List of figures

7.6	Cellular uptake of TNPs in U87 MG cells (A) and (B) untreated U-87 MG cells	189
7.7	Cellular uptake of (A) TNPs, (B) HA-TNPs and (C) CS-TNPs in U-87 MG cells	190
7.8	Elucidation of cellular uptake mechanism of TNPs on U-87 MG cells. Data is represented as mean \pm SD (n = 3)	191
7.9	Elucidation of cellular uptake mechanism of (A) HA-TNPs and (B) CS-TNPs on U-87 MG cells. Data is represented as mean \pm SD (n = 3)	192
7.10	Qualitative determination of ROS generation (A) TMZ, (B) TNPs, (C) HA-TNPs and (D) CS-TNPs	193
7.11	Quantitative determination of ROS generation (A) TMZ, (B) TNPs, (C) HA-TNPs and (D) CS-TNPs. Data represented as mean \pm SD	194
7.12	<i>In vitro</i> scratch assay to determine effect of different formulations on cell migration: (A) Control, (B) TMZ, (C) TNPs, (D) HA-TNPs and (E) CS-TNPs	195
Chapter 8		
8.1	<i>In vivo</i> pharmacokinetic study: Plasma concentration-time profile of TMZ, TNPs, HA-TNPs and CS-TNPs after intravenous injection in rats (n=6) and data is represented as mean \pm SD	201
8.2	Biodistribution pattern of TMZ, TNPs, HA-TNPs and CS-TNPs	203
Chapter 9		
9.1	Optimization of aqueous: organic phase ratio	215
9.2	Selection of organic solvent as desolvating agent	216
9.3	Optimization of Gluteraldehyde amount	218
9.4	Optimization of rate of addition of organic phase	219
9.5	Optimization of drug concentration	220
9.6	Optimization of stirring speed	221
9.7	Particle size and PDI of optimized LNPs	225
9.8	Particle size and PDI of optimized Lf-LNPs	225
9.9	Zeta potential of optimized LNPs	226
9.10	Zeta potential of optimized Lf-LNPs	227

9.11	FTIR spectrum of BSA, LND, LF, physical mixture, Lf-PNPs and Lf-LNPs	228
9.12	DSC thermogram of (A) BSA, (B) LND, (C) Lf-PNPs and (D) Lf-LNPs	230
9.13	XRD diffractograms of (A) BSA, (B) LND, (C) Physical mixture (PM), (D) PNPs, (E) LNPs, (F) Lf-PNs and (G) Lf-LNPs	231
9.14	TEM image of (A) LNPs and (B) Lf-LNPs	232
9.15	<i>In vitro</i> drug release study of LND, LNPs and Lf-LNPs in phosphate buffer pH 7.4	233
Chapter 10		
10.1	<i>In vitro</i> BBB passage studies for pure LND, PNPs, LNPs, Lf-PNPs and Lf-LNPs after 2h, 24h and 48h	242
10.2	<i>In vitro</i> cell viability study in U-87MG cells after 48 h. Data is represented as mean \pm SD (n = 3)	243
10.3	Cellular uptake of LND, LNPs, Lf-PNPs and Lf-LNPs in U87 MG cells. Data is represented as mean \pm SD.	244
10.4	Elucidation of cellular uptake mechanism of LND, LNPs, LF-PNPs and Lf-LNPs (A) percent cellular uptake and (B) reduction in cellular uptake. Data is represented as mean \pm SD (n = 3)	245
10.5	Lactoferrin receptor binding assay of LNPs and Lf-LNPs (A) % uptake and (B) % reduction in uptake	246
10.6	Quantitative determination of ROS generation of LND, PNPs, LF-PNPs, LNPs and Lf-LNPs. Data represented as mean \pm SD	247
10.7	<i>In vitro</i> scratch assay to determine effect of different formulations on cell migration: (A) Control, (B) LND, (C) LNPs and (D) Lf-LNPs	248
Chapter 11		
11.1	Graphical representation of average changes in the % tumor growth of untreated (model control), pure LND (standard control) and Lf-LNPs treated mice. Error bars represent SEM, (n=3)	254
11.2	Excised tumor image of the animals treated with different test sample (A) untreated group (saline treated), (B) standard control (LND treated) and (C) Lf-LNPs treated after terminal of study (three each)	254

